TRAPANI, DARIO
TRAPANI, DARIO
Dipartimento di Oncologia ed Emato-Oncologia
Advancing oncology innovation under persistent constraints
2026 D. Trapani, G. Curigliano
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study
2026 C. Valenza, J.D. Etessami, M. Milano, N. Papadopoulos, M. Alvino, G. Antonarelli, N. Bianco, C. Sangalli, D. Trapani, G. Pravettoni, E. Omodeo Salè, R. Passerini, M. Colleoni, E. Munzone, G. Curigliano
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
2026 F. Lynce, C. Valenza, S.M. Niman, F. Bertucci, M. Kai, S. Ryan, E. Troll, R.M. Layman, K.A. Fanucci, A. Giordano, A. Nasrazadani, F. Nakhlis, J. Bellon, L. Warren, C. Block, S. Schumer, A. Lucci, S. Krishnamurthy, D. Trapani, F. Lerebours, F. Dalenc, C. Levy, T. Petit, M. Leheurteur, T. Bachelot, O. Tredan, J.M. Ribeiro, B. Pistilli, P. Zagami, S. Ladoire, L. Lopez Almeida, C. Zemmour, L.A. Carey, S.M. Tolaney, V. Valero, G. Curigliano, M.M. Regan, A. Goncalves, W.A. Woodward
Genomic landscape, immune microenvironment and survival in male versus female breast cancer
2026 D. Trapani, S.K. Deshmukh, T. Samec, S. Wu, J. Xiu, P. Walker, D.L. Abravanel, P. Advani, P.M. Spanheimer, N.U. Lin, G. Curigliano, S.L. Graff, M. Lustberg, G.W. Sledge, S.M. Tolaney, J.P. Leone
Impact of breast cancer on sexuality and psycho-physical wellbeing: Survey analysis
2026 P. Zagami, B.T. Salimbeni, E.P. Preti, A. Esposito, A. Marra, D. Trapani, E. Munzone, M. Mazza, S. Martella, I. Durosini, S. Perazzo, R. Marsicano, P.P. Maria Berton Giachetti, G. Curigliano, C. Criscitiello, G. Pravettoni
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions
2026 J. Iranzo, E. Giordano, R.M. Marsicano, D. Trapani, A. Marra, C. Belli, P. Zagami, P.P.M. Berton Giachetti, E. Ferraro, I. Minchella, E. Crimini, G. Curigliano
A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer
2026 L. Boscolo Bielo, D. Trapani, P. Razavi, S. Chandarlapaty, Y. Zhan, G. Curigliano
Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study
2026 N. Bianco, C. Valenza, M. Milano, R. Multinu, E. Battaiotto, M. Cavallone, G. Malvezzi, D. Trapani, P. Della Vigna, G. Bonomo, G.M. Varano, D. Maiettini, M.G. Pitoni, C. Sangalli, E. Munzone, G. Curigliano, M.A. Colleoni, F. Orsi
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study
2026 C. Valenza, Y. Zheng, M. Milano, D. Trapani, E. Giordano, L. Guidi, P.P.M. Berton Giachetti, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, F. Conforti, E. Pagan, V. Bagnardi, G.J. Kirkner, C. Sangalli, K.E. Dibble, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
2026 G. Corso, C. Andreon, C. La Vecchia, E.I. Bottazzoli, G. Abruzzese, K. Favilla, O. Citterio, E. Spoldi, S. Di Silvestre, A.M. De Scalzi, A. Polizzi, E. Meduri, D. Trapani, L. Nicosia, F. Pesapane, D. Bossi, E. Brogi, S. Shen, R. Mukhtar, C. Criscitiello, P. Veronesi, S. Gandini, F. Magnoni, G. Curigliano
Do all patients with early breast cancer meeting the NATALEE criteria benefit from adjuvant ribociclib?
2025 C. Valenza, D. Trapani, G. Curigliano
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
2025 N.I. Cherny, S.F. Oosting, U. Dafni, N.J. Latino, M. Galotti, P. Zygoura, G. Dimopoulou, T. Amaral, J. Barriuso, A. Calles, B. Kiesewetter, C. Gomez-Roca, B. Gyawali, M. Piccart, A. Passaro, F. Roitberg, N. Tarazona, D. Trapani, G. Curigliano, R. Wester, G. Zarkavelis, C. Zielinski, E.G.E. De Vries
Circulating tumor DNA: a biomarker for oncology drug development in phase I clinical trials?
2025 R. Asnaghi, R.M. Marsicano, V. Fuorivia, G. Malvezzi, J.D. Etessami, D. Izzo, C. Valenza, G. Curigliano, D. Trapani
Current controversies in the use of Oncotype DX in early breast cancer
2025 P.P.M. Berton Giachetti, A.C. Schianca, D. Trapani, A. Marra, A. Toss, C. Marchiò, M.V. Dieci, O.D. Gentilini, C. Criscitiello, K. Kalinsky, J.A. Sparano, G. Curigliano
Beyond Boundaries in ERBB2-Positive Brain Metastatic Breast Cancer
2025 D. Trapani, C. Valenza, G. Curigliano
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
2025 B. Taurelli Salimbeni, F. Giudici, C. Pescia, P.P.M. Berton Giachetti, R. Scafetta, P. Zagami, A. Marra, D. Trapani, A. Esposito, S. Scagnoli, B. Cerbelli, A. Botticelli, E. Munzone, N. Fusco, C. Criscitiello, G. Curigliano
Metronomic Chemotherapy in Breast Cancer as a Strategy to Deliver More Sustainable and Less Toxic Treatments: Time to Debunk the Myth?
2025 E. Battaiotto, S. D'Ambrosio, D. Trapani, G. Curigliano
ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update
2025 N.I. Cherny, D. Trapani, M. Galotti, M. Saar, G. Bricalli, F. Roitberg, B. Gyawali, G. Curigliano, J. Blay, K. Meier, N.J. Latino, E.G.E. De Vries
From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials
2025 E. Almuradova, D. Izzo, S. Gandini, A. Gaeta, E. Giordano, C. Valenza, G. Antonarelli, D. Trapani, G. Curigliano